IFN-lambda therapy: Current status and future perspectives

Drug Discovery Today

Volumn 21, Issue 1, 2016, Pages 167-171

  Lasfar, Ahmed ^a,c   Zloza, Andrew ^b   Cohen Solal, Karine A ^b  

^a RUTGERS UNIVERSITY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; EPSILON INTERFERON; GAMMA INTERFERON; INTERFERON; KAPPA INTERFERON; OMEGA INTERFERON; PEGINTERFERON LAMBDA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT;

AUTOIMMUNE DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; NEOPLASM; ONCOLOGY; REVIEW; VIRUS INFECTION; ANIMAL; AUTOIMMUNE DISEASES; DRUG EFFECTS; INNATE IMMUNITY; NEOPLASMS; VIRUS DISEASES;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; AUTOIMMUNE DISEASES; HUMANS; IMMUNITY, INNATE; INTERFERONS; NEOPLASMS; VIRUS DISEASES;

EID: 84960262412     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.10.021     Document Type: Review

References (66)

1. S.V. Kotenko, and et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex Nat. Immunol. 4 2003 69 77
2. P. Sheppard, and et al. IL-28, IL-29, their class II cytokine receptor IL-28R Nat. Immunol. 4 2003 63 68
3. S. Pestka, and et al. Interferons, interferon-like cytokines, and their receptors Immunol. Rev. 202 2004 8 32
4. L. Koumbi Current and future antiviral drug therapies of hepatitis B chronic infection World J. Hepatol. 7 2015 1030 1040
5. S.M. Laidlaw, and L.B. Dustin Interferon lambda: opportunities, risks, and uncertainties in the fight against HCV Front. Immunol. 5 2014 545
6. N. Boyer, and P. Marcellin Pathogenesis, diagnosis and management of hepatitis C J. Hepatol. 32 Suppl. 1 2000 98 112
7. N. Antaki, and et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report Liver Int. 30 2010 342 355
8. E. Regnier-Rosencher, and et al. Treatments for classic Kaposi sarcoma: a systematic review of the literature J. Am. Acad. Dermatol. 68 2013 313 331
9. D.W. Kimberlin Pharmacotherapy of recurrent respiratory papillomatosis Expert Opin. Pharmacother. 3 2002 1091 1099
10. J.W. Schoggins Interferon-stimulated genes: roles in viral pathogenesis Curr. Opin. Virol. 6 2014 40 46
11. J.W. Schoggins, and et al. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity Nature 505 2014 691 695
12. J.W. Schoggins, and et al. A diverse range of gene products are effectors of the type I interferon antiviral response Nature 472 2011 481 485
13. F.H. Duong, and et al. IFN-lambda receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-lambda3 genotype and with nonresponsiveness to IFN-alpha therapies J. Exp. Med. 211 2014 857 868
14. J. Buckland Botulism beaten Nat. Rev. Immunol. 2 2002 628
15. V. Shankaran, and et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity Nature 410 2001 1107 1111
16. P.R. Errante, and et al. The use of interferon-gamma therapy in chronic granulomatous disease Recent Pat. Antiinfect. Drug Discov. 3 2008 225 230
17. A. Stiff, and W. Carson III Investigations of interferon-lambda for the treatment of cancer J. Innate Immun. 7 2015 243 250
18. H.M. Lazear, and et al. Interferon-lambda: immune functions at barrier surfaces and beyond Immunity 43 2015 15 28
19. J.A. Langer, and et al. The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions Cytokine Growth Factor Rev. 15 2004 33 48
20. R.K. Durbin, and et al. Interferon induction and function at the mucosal surface Immunol. Rev. 255 2013 25 39
21. T. Mahlakoiv, and et al. Leukocyte-derived IFN-alpha/beta and epithelial IFN-lambda constitute a compartmentalized mucosal defense system that restricts enteric virus infections PLoS Pathog. 11 2015 e1004782
22. L. Prokunina-Olsson, and et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus Nat. Genet. 45 2013 164 171
23. D. Booth, and J. George Loss of function of the new interferon IFN-lambda4 may confer protection from hepatitis C Nat. Genet. 45 2013 119 120
24. K. Ray Hepatitis: new gene IFNL4 is associated with impaired clearance of HCV Nat. Rev. Gastroenterol. Hepatol. 10 2013 63
25. A. Egli, and et al. The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections Emerg. Microbes Infect. 3 2014 e51
26. Y.F. Lu, and et al. Interferon-lambda4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden Virology 476 2015 334 340
27. T.R. O'Brien, and et al. IFN-lambda4: the paradoxical new member of the interferon lambda family J. Interferon Cytokine Res. 34 2014 829 838
28. S.J. Griffiths, and et al. The role of interferon-lambda locus polymorphisms in hepatitis C and other infectious diseases J. Innate Immun. 7 2015 231 242
29. P. Hermant, and T. Michiels Interferon-lambda in the context of viral infections: production, response and therapeutic implications J. Innate Immun. 6 2014 563 574
30. H.H. Hoffmann, and et al. Interferons and viruses: an evolutionary arms race of molecular interactions Trends Immunol. 36 2015 124 138
31. A. Lasfar, and et al. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma Cancer Res. 66 2006 4468 4477
32. M.T. Catanese, and M. Dorner Advances in experimental systems to study hepatitis C virus in vitro and in vivo Virology 479-480 2015 221 233
33. M. Dorner, and et al. Completion of the entire hepatitis C virus life cycle in genetically humanized mice Nature 501 2013 237 241
34. I. Gresser, and F. Belardelli Endogenous type I interferons as a defense against tumors Cytokine Growth Factor Rev. 13 2002 111 118
35. A. Lasfar, and et al. Critical role of the endogenous interferon ligand-receptors in type I and type II interferons response Immunology 142 2014 442 452
36. A. Lasfar, and et al. Interferon lambda: a new sword in cancer immunotherapy Clin. Dev. Immunol. 2011 2011 349575
37. L. Ronnblom, and M.L. Eloranta The interferon signature in autoimmune diseases Curr. Opin. Rheumatol. 25 2013 248 253
38. A.J. Muir, and et al. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection J. Hepatol. 61 2014 1238 1246
39. P.M. George, and et al. Pharmacology and therapeutic potential of interferons Pharmacol. Ther. 135 2012 44 53
40. M.H. Heim 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end Nat. Rev. Immunol. 13 2013 535 542
41. J.M. Kirkwood, and et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy J. Clin. Oncol. 20 2002 3703 3718
42. E. Jonasch, and F.G. Haluska Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities Oncologist 6 2001 34 55
43. P.M. George, and et al. Evidence for the involvement of type I interferon in pulmonary arterial hypertension Circ. Res. 114 2014 677 688
44. L. Savale, and et al. Pulmonary arterial hypertension in patients treated with interferon Eur. Respir. J. 44 2014 1627 1634
45. G. Simonneau, and et al. Updated clinical classification of pulmonary hypertension J. Am. Coll. Cardiol. 62 Suppl. 25 2013 D34 D41
46. H. Barth Hepatitis C virus: is it time to say goodbye yet? Perspectives and challenges for the next decade World J. Hepatol. 7 2015 725 737
47. M.P. Manns, and T. von Hahn Novel therapies for hepatitis C - one pill fits all? Nat. Rev. Drug Discov. 12 2013 595 610
48. I. Gresser Interferon should be used to prevent and/or treat Ebola virus disease Biomed. Pharmacother. 71 2015 29
49. M.A. Postow, and et al. Immune checkpoint blockade in cancer therapy J. Clin. Oncol. 33 2015 1974 1982
50. W. Abushahba, and et al. Antitumor activity of type I and type III interferons in BNL hepatoma model Cancer Immunol. Immunother. 59 2010 1059 1071
51. A. Lasfar A new ally for interferon-alpha in cancer therapy Clin. Cell. Immunol. 3 2012 4 5
52. E.A. Voigt, and J. Yin Kinetic differences and synergistic antiviral effects between type I and type III interferon signaling indicate pathway independence J. Interferon Cytokine Res. 35 2015 734 747
53. C. Odendall, and et al. Diverse intracellular pathogens activate type III interferon expression from peroxisomes Nat. Immunol. 15 2014 717 726
54. P.P. Hernandez, and et al. Interferon-lambda and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection Nat. Immunol. 16 2015 698 707
55. M.K. Crow Interferon-alpha: a therapeutic target in systemic lupus erythematosus Rheum. Dis. Clin. North Am. 36 2010 173 186
56. J.C. Hall, and A. Rosen Type I interferons: crucial participants in disease amplification in autoimmunity Nat. Rev. Rheumatol. 6 2010 40 49
57. G. Obermoser, and V. Pascual The interferon-alpha signature of systemic lupus erythematosus Lupus 19 2010 1012 1019
58. L. Ronnblom, and et al. The type I interferon system in the development of lupus Semin. Immunol. 23 2011 113 121
59. Y. Ioannou, and D.A. Isenberg Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy Arthritis Rheum. 43 2000 1431 1442
60. T. Okanoue, and et al. Side effects of high-dose interferon therapy for chronic hepatitis C J. Hepatol. 25 1996 283 291
61. J.J. Hooks, and et al. Immune interferon in the circulation of patients with autoimmune disease N. Engl. J. Med. 301 1979 5 8
62. H.H. Borba, and et al. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis BioDrugs 28 2014 211 228
63. M. Petri, and et al. Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study Arthritis Rheum. 65 2013 1011 1021
64. Y. Yao, and et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus Arthritis Rheum. 60 2009 1785 1796
65. P. Fredlund, and et al. Peginterferon lambda-1a is associated with a low incidence of autoimmune thyroid disease in chronic hepatitis C J. Interferon Cytokine Res. 35 2015 841 843
66. K. Blazek, and et al. IFN-lambda resolves inflammation via suppression of neutrophil infiltration and IL-1beta production J. Exp. Med. 212 2015 845 853